Fig. 3: Improved survival in PDAC-bearing mice treated with the combination of VIP-R antagonists and anti-PD-1 is T cell-dependent. | Nature Communications

Fig. 3: Improved survival in PDAC-bearing mice treated with the combination of VIP-R antagonists and anti-PD-1 is T cell-dependent.

From: Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma

Fig. 3

a Kaplan–Meier survival plots of C57BL/6 mice with subcutaneously implanted KPC.Luc, MT5 or Panc02 tumors are stratified by treatment. Both male and females were used in equal proportions for experiments utilizing subcutaneous implantation of KPC-Luc cancer cells. Female mice were used for experiments involving subcutaneosu implantation of MT5 and Panc02 cancer cell lines. b Spider plots for KPC.Luc corresponds to results in panel (a) as measured by Vernier calipers following subcutaneous tumor implantation in 4 different treatment groups. Median tumor volumes are represented as a dashed gray line (┉). In panels (a, b), tumor cells were implanted in female or male mice with females receiving 10 ug ANT308 and males receiving 20 µg of ANT308 due to higher male mice body weight compared to female mice. Kaplan–Meier survival plots of (c) C57BL/6 mice receiving monoclonal CD4 and/or CD8 monoclonal antibodies (d) CD4KO or (e) CD8KO mice compared to wild-type CD57BL/6 mice with subcutaneously implanted KPC.Luc tumors, stratified by treatment. Statistical differences for Kaplan–Meier curves are calculated via Log-rank test. *p < 0.05, **p < 0.01 and ***p < 0.001, ****p < 0.0001.

Back to article page